A class action lawsuit against Cerevel Therapeutics, Bain Capital Investors, and Pfizer led to Pfizer's recent stock decline, worsened by market turmoil. Despite positive news like receiving marketing authorization in Europe, Pfizer's stock was overshadowed by market setbacks.